Table 1 |
||||||||||
|
Baseline characteristics of the study population and the factors found in PCA |
||||||||||
|
Component |
||||||||||
|
Variable |
Baseline frequency |
1 |
2 |
3 |
4 |
5 |
6 |
7 |
8 |
9 |
|
|
||||||||||
|
Age at inclusion (years, mean ± SD) |
59.2 (16.2) |
0.761 |
||||||||
|
Female gender (n, %) |
219 (68.9) |
0.448 |
0.394 |
|||||||
|
Subacute onset of symptoms (versus insidious) |
188 (59.1) |
0.592 |
-0.306 |
0.316 |
||||||
|
Morning stiffness (min; mean ± SD) |
103.18 (112.0) |
-0.496 |
0.484 |
|||||||
|
Fatigue (VAS; mean ± SD) |
45.1 (29.9) |
-0.389 |
0.522 |
|||||||
|
Symptom duration (days; mean ± SD) |
172.1 (180.2) |
0.394 |
-0.349 |
0.455 |
||||||
|
Family history of RA (n, %) |
62 (19.5) |
-0.326 |
0.594 |
0.380 |
||||||
|
Past or present smoking (n, %) |
128 (40.3) |
0.652 |
0.375 |
|||||||
|
Fever (n, %) |
22 (6.9) |
-0.319 |
-0.426 |
|||||||
|
Involvement of small/large joints (n, %) |
a |
0.604 |
||||||||
|
Symmetry of involved joints (n, %) |
216 (67.9) |
-0.379 |
0.308 |
0.331 |
0.370 |
|||||
|
Involvement of upper/lower extremities |
b |
0.602 |
-0.348 |
|||||||
|
Inflammatory back pain (n, %) |
16 (5.0) |
0.466 |
0.531 |
0,321 |
||||||
|
Skin abnormalities (N, %)c |
56 (18.1) |
0.374 |
||||||||
|
Swollen joint count (mean ± SD)d |
11.3 (8.5) |
0.445 |
0.365 |
|||||||
|
CRP (mg/L; mean ± SD) |
30.10 (34.4) |
0.315 |
0.434 |
0.512 |
||||||
|
RF (IU/ml) (mean ± SD)e |
7.12 (19.5) |
0.305 |
-0.345 |
0.315 |
-0.602 |
|||||
|
MCV positivity (n, %) |
59 (18.6) |
0.470 |
0.376 |
-0.321 |
||||||
|
Erosive disease at baseline (n, %) |
202 (63.5) |
0.642 |
0.332 |
|||||||
|
Explained variance per component (%) |
10.0 |
8.6 |
8.0 |
7.4 |
6.8 |
6.5 |
5.6 |
5.5 |
5.4 |
|
|
|
||||||||||
|
Involvement of upper extremities: shoulder, elbow, wrist, or hand joints; involvement of lower extremities: joints of hip, knee, ankle, feet or toe joints.aInvolvement of small/large joints: in 163 patients (51.3%), only small joints of hands and feet were involved. In 53 patients (16.7%) only large joints were involved. In 93 patients (29.2%), both small and large joints were involved.aInvolvement of upper/lower extremities: in 156 patients (49.1%) only joints in the upper extremities were involved. In 28 patients (8.8%), only joints in the lower extremities were involved. In 96 (30.2%) patients, joints in both lower and upper extremities were involved.cSkin abnormalities: absence or presence of dermatological abnormalities such as psoriatic lesions, ulcers, rheumatoid nodules and so on.dSwollen Joint Count: 44-Swollen Joint Count.eAnalyses were performed on RF in groups (less than reference value, 1 to 3 times reference value, or more than 3 times reference value). CRP, C-reactive protein; MCV, mutated citrullinated vimentin; RF, rheumatoid factor; VAS, visual analogue scale. |
||||||||||
|
De Rooy et al. Arthritis Research & Therapy 2011 13:R180 doi:10.1186/ar3505 |
||||||||||
